FDA approvals are critical milestones for medical device companies, often leading to increased product adoption and market expansion. This approval allows Boston Scientific to target a broader patient population, potentially boosting sales and enhancing its market position in pain management solutions. Given the prevalence of chronic low back and leg pain, and the limitation of treatment options for patients without prior surgery, this approval could significantly impact Boston Scientific's revenue and market share in the short term.